- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in Journal
Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today announced that data assessing the safety and efficacy of serlopitant, the company’s NK-1 receptor antagonist, in treating chronic pruritus was published in the Journal of the …
Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today announced that data assessing the safety and efficacy of serlopitant, the company’s NK-1 receptor antagonist, in treating chronic pruritus was published in the Journal of the American Academy of Dermatology (JAAD).
As quoted in the press release:
The safety and efficacy results of this study were previously presented at the 26th European Academy of Dermatology and Venereology conference by Professor Dr. Sonja Ständer, Professor of Dermatology and Neurodermatology, head of the Center for Chronic Pruritus of the University Hospital Münster, Germany. Data on the early onset of effect of serlopitant in this study were presented at the same conference by Paul Kwon, MD, Chief Medical Officer of Menlo Therapeutics.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.